Table 2 Demographic data of the patients with AD at baseline by disease severity
CDR = 0.5 (n = 20) | CDR = 1.0 (n = 208) | CDR = 2.0 (n = 81) | CDR = 3.0 (n = 12) | P value* | |
|---|---|---|---|---|---|
Male patients, n (%) | 13 (65.0%) | 104 (50.0%) | 49 (60.5%) | 7 (58.3%) | 0.29 |
Age (years) | 79.2 (5.4) | 80.3 (6.0) | 80.6 (6.7) | 82.5 (7.7) | 0.49 |
Education (years) | 9.6 (4.9) | 10.2 (4.5) | 9.7 (4.3) | 12.4 (3.6) | 0.22 |
Disease duration (months) | 24.8 (16.7) | 51.1 (48.6) | 56.4 (39.7) | 99.3 (71.6) | < 0.01 |
BMI (kg/m2) | 24.5 (3.4) | 23.6 (3.2) | 23.9 (3.5) | 20.3 (3.1) | 0.03 |
MMSE | 22.8 (2.9) | 19.9 (4.2) | 14.2 (5.0) | 3.7 (3.5) | < 0.01 |
NPI-agitation/aggression | 5.5 (13.3) | 5.5 (10.0) | 10.1 (13.5) | 14.8 (22.1) | < 0.01 |
NPI-mood | 6.3 (12.9) | 4.7 (8.6) | 6.5 (8.8) | 9.8 (16.2) | 0.15 |
NPI-frontal | 5.1 (10.1) | 4.6 (8.9) | 8.0 (10.5) | 11.3 (19.5) | 0.01 |
ApoE4 carrier | 6 (30%) | 77 (37.0%) | 44 (54.3%) | 7 (58.3%) | < 0.01 |
Plasma clusterin level (μg/ml) | 253.6 (36.9) | 244.9 (36.6) | 255.9 (40.9) | 252.7 (38.9) | 0.15 |
Aβ1–40 (pg/ml) | 144.7 (28.7) | 160.4 (47.8) | 154.7 (55.5) | 162.8 (87.2) | 0.51 |
Aβ1–42 (pg/ml) | 38.9 (11.9) | 34.1 (13.9) | 33.6 (15.6) | 57.4 (87.4) | < 0.01 |
Ratio of Aβ1–42/Aβ1–40 (%) | 26.9 (5.7) | 21.8 (9.2) | 22.5 (10.8) | 28.3 (17.8) | 0.08 |